Close Menu

NEW YORK (360Dx) – Metabolic dysregulation has emerged as a major focus for research into autism spectrum disorder (ASD) with a number of academic groups and commercial outfits looking to such abnormalities to diagnose and treat the condition.

Last year, Madison, Wisconsin-based Stemina Biomarker Discovery launched its first metabolomic test for diagnosing ASD through its NeuropointDx division.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Dec
05
Sponsored by
Amazon

The discovery of microbial cell-free DNA has propelled the introduction of new technologies that can be leveraged for next-generation diagnostic assays. Previously inaccessible genomic information can now be comprehensively surveyed for microorganisms, all from a single blood draw.